Assessing response of therapy for acute and chronic graft-versus-host disease

References

• Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75(4), 1024–1030 (1990).
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D, Ruiz-Argüelles GJ, del Carmen Tarín-Arzaga L et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 14(1), 10–15 (2008).
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim HT, Ho VT et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 38(4), 305–310 (2006).
   PubMed Web of Science ®Google Scholar
• Rowlings PA, Przepiorka D, Klein JP et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br. J. Haematol. 97(4), 855–864 (1997).
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 11(12), 945–956 (2005).
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N. Engl. J. Med. 314(12), 729–735 (1986).
   PubMed Web of Science ®Google Scholar
• Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76(8), 1464–1472 (1990).
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Storer BE, Boeckh M et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 113(13), 2888–2894 (2009).
   PubMed Web of Science ®Google Scholar
• Lee SJ. Have we made progress in the management of chronic graft-vs-host disease? Best Pract. Res. Clin. Haematol. 23(4), 529–535 (2010).
   PubMed Web of Science ®Google Scholar
• MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 115(26), 5412–5417 (2010).
   PubMed Web of Science ®Google Scholar
• Levine JE, Logan B, Wu J et al.; Blood and Marrow Transplant Clinical Trials Network. Graft-versus-host disease treatment: predictors of survival. Biol. Blood Marrow Transplant. 16(12), 1693–1699 (2010).
   PubMed Web of Science ®Google Scholar
• Saliba RM, Couriel DR, Giralt S et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. 47(1), 125–131 (2012).
   PubMedGoogle Scholar
• Pavletic SZ, Martin P, Lee SJ et al.; Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol. Blood Marrow Transplant. 12(3), 252–266 (2006).
   PubMed Web of Science ®Google Scholar
• Levine JE, Logan BR, Wu J et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 119(16), 3854–3860 (2012).
   PubMed Web of Science ®Google Scholar
• MacMillan ML, Weisdorf DJ, Wagner JE et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol. Blood Marrow Transplant. 8(7), 387–394 (2002).
   PubMed Web of Science ®Google Scholar
• Alousi AM, Weisdorf DJ, Logan BR et al.; Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 114(3), 511–517 (2009).
   PubMed Web of Science ®Google Scholar
• Martin PJ, Nash RA. Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 12(1 Suppl. 2), 31–36 (2006).
   Web of Science ®Google Scholar
• Martin PJ, McDonald GB, Sanders JE et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 10(5), 320–327 (2004).
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3), 555–562 (1990).
   PubMed Web of Science ®Google Scholar
• Chronic GVHD Consortium. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol. Blood. Marrow Transplant. 17(8), 1114–1120 (2011).
   PubMed Web of Science ®Google Scholar
• Arai S, Jagasia M, Storer B et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 118(15), 4242–4249 (2011).
   PubMed Web of Science ®Google Scholar
• Paczesny S, Krijanovski OI, Braun TM et al. A biomarker panel for acute graft-versus-host disease. Blood 113(2), 273–278 (2009).
   PubMed Web of Science ®Google Scholar
• Paczesny S, Braun TM, Levine JE et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci. Transl. Med. 2(13), 13ra2 (2010).
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Harris AC, Greenson JK et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 118(25), 6702–6708 (2011).
   PubMed Web of Science ®Google Scholar
• Schultz KR, Miklos DB, Fowler D et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol. Blood Marrow Transplant. 12(2), 126–137 (2006).
   PubMed Web of Science ®Google Scholar